Transcriptomics

Dataset Information

0

TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924


ABSTRACT: Background: The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is a novel oral antimetabolite with a distinct mechanism of action from fluoropyrimidines. We evaluated the antitumor efficacy of TAS-102, irinotecan and bevacizumab in patients with pre-treated, advanced colorectal adenocarcinoma in a multicenter, phase II, single-arm study. Methods: Patients with advanced colorectal adenocarcinoma who had progressed after oxaliplatin and fluoropyrimidine and were eligible for treatment with bevacizumab were treated with irinotecan, bevacizumab, and TAS-102 in 28-day cycles. The primary endpoint was progression-free survival (PFS). Results: We enrolled 35 evaluable patients. The study was positive. The median PFS was 7.9 (90% CI 6.2-11.8) months (vs. 6 months in historical control, p=0.018). The median overall survival was 16.5 (90% CI 9.8-17.5) months. Sixty-seven percent of patients experienced grade 3 or higher treatment-related adverse events. The most common toxicities were hematological (neutropenia) and gastrointestinal (diarrhea, nausea, and vomiting). Conclusions: Irinotecan, TAS-102 and bevacizumab is an active 2nd line therapy for patients with metastatic colorectal adenocarcinoma. Neutropenia is common and can affect dose density/intensity mandating use of G-CSF. A randomized study versus standard of care therapy is warranted.

ORGANISM(S): Homo sapiens

PROVIDER: GSE275628 | GEO | 2024/08/26

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-03-31 | GSE226221 | GEO
2018-11-21 | GSE110785 | GEO
2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress
| PRJNA1152270 | ENA
2013-12-18 | E-GEOD-53127 | biostudies-arrayexpress
2013-12-18 | GSE53127 | GEO
2014-11-14 | E-GEOD-63216 | biostudies-arrayexpress
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
2011-01-07 | E-GEOD-25698 | biostudies-arrayexpress
2013-01-15 | E-MTAB-951 | biostudies-arrayexpress